Tag Archive | "EGFR"
YM Biosciences reports positive nimotuzumab four-year survival data
Source: www.reuters.com Author: press release YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that an oral presentation at the American Society for Therapeutic Radiology and Oncology (ASTRO) 2009 Annual Meeting reported positive 48-month survival data for its [...]
Continue reading...Erbitux® may improve treatment of squamous cell carcinoma of the esophagus
Saturday, October 3, 2009
Source: professional.cancerconsultants.com Author: staff Researchers from Germany have reported that Erbitux® (cetuximab) improves response rate, time to disease progression, and overall survival of patients with metastatic squamous cell carcinoma receiving Platinol® (cisplatin) and 5-FU. The details of this study appeared in the October 2009 issue of Annals of Oncology.[1] Esophageal cancer is relatively common and [...]
Continue reading...Tips on managing the rash associated with EGFR inhibitors
Monday, September 28, 2009
Source: OncologySTAT (www.oncologystat.com) Author: OncologySTAT Editorial Team Nurses at Duke University Hospital in Durham, NC, have developed a treatment algorithm for the rash that frequently occurs with use of epidermal growth factor receptor (EGFR) inhibitors. “We want to help sustain patients so they can continue to get their therapy and maintain their quality of life,” [...]
Continue reading...Gefitinib shows promise as treatment for advanced head and neck cutaneous squamous cell carcinoma
Wednesday, July 15, 2009
Source: www.docguide.com Author: Louise Gagnon Gefitinib produces a significant response in patients with advanced head and neck cutaneous squamous cell carcinoma (cSCC) prior to standard treatment, according to a phase 2 study presented here at the 2nd World Congress of the International Academy of Oral Oncology (IAOO). “We want to shrink the tumour as much [...]
Continue reading...Vanderbilt-Ingram Cancer Center’s research efforts highlighted at annual cancer conference
Saturday, June 27, 2009
Source: www.mc.vanderbilt.edu Author: Dagny Stuart A new drug which targets a genetic mutation found in more than 50 percent of melanoma cases, 10 percent to 15 percent of colorectal tumors and 8 percent of other solid tumors, caused tumor shrinkage and extended progression-free survival among patients during a recent Phase 1 clinical trial. Igor Puzanov, [...]
Continue reading...DNA therapy for head and neck cancer
Tuesday, June 2, 2009
Source: Nature Reviews Clinical Oncology 6, 302 (June 2009) Author: Mandy Aujla Researchers have developed an antisense EGFR sequence to target EGFR, and found that this approach was safe and effective in patients with advanced squamous-cell carcinoma of the head and neck. Standard treatment for this type of cancer is suboptimal. Various drugs have been [...]
Continue reading...Personalised cancer diagnosis
Wednesday, May 13, 2009
Source: www.economist.com Author: staff If researchers could identify what it is that makes a tissue tumorous, they might be able to develop drugs aimed precisely at the cause of the cancer. At present, they know that certain molecules become active in tumours found in certain parts of the body. Both head-and-neck cancers and breast cancers, [...]
Continue reading...Monoclonal Antibody Drugs for Cancer Treatment
Sunday, April 5, 2009
Source: www.newswise.com Author: staff The strategy of using monoclonal antibodies for cancer treatment was first described in the late 1970s with the promise that they could be developed into therapies that were highly specific to cancer cells, killing them with few or no side effects. For several types of cancer, monoclonal antibodies have already offered [...]
Continue reading...Tarceva® and Avastin® safe and effective for patients with squamous-cell head and neck carcinoma
Friday, March 6, 2009
Source: professional.cancerconsultants.com Author: staff Researchers from the National Cancer Institute and the University of Chicago have reported that the combination of Tarceva® (erlotinib) and Avastin® (bevacizumab) is well tolerated and produces sustained responses in some patients with recurrent or metastatic squamous-cell head and neck carcinoma. The details of this study appeared in the March 2009 [...]
Continue reading...YM Biosciences’s drug selected for Phase III head and neck cancer study
Wednesday, January 7, 2009
Source: www.pharmaceutical-business-review.com Author: staff YM BioSciences, an oncology company, has announced that the National Cancer Centre of Singapore has selected nimotuzumab, the company’s EGFR-targeting drug, for evaluation in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The National Cancer Centre of Singapore (NCCS) said that it [...]
Continue reading...- Accuracy of Dentists in the Clinical Diagnosis of Oral Lesions
- New Evaluation for HPV16 Related Cancers Using "Pap-Test Equivalent"
- New Study Indicates Tobacco Industry Was Aware of Their Own Products Dangers
- Increase in oral cancers linked to HPV
- Systems Strategies To Support Cancer Screening in U.S. Primary Care Practice
- Study Finds- Fewer Dying from Throat & Mouth Cancer in the U.S.
- UI professors: HPV editorial misses the mark
- Girls-Only Vaccine Could Be Best Weapon Against HPV
- Many Head and Neck Cancer Survivors Face Eating Problems
- The Gardasil Problem: How The U.S. Lost Faith In A Promising Vaccine
- hilllaguna: This reply originally posted on the Knight Science...
- Brian Hill: I wonder who paid for this bit of research to be d...
- Brian Hill: Maybe in the Netherlands this mathematical model f...
- Brian Hill: The foundation would like to commend the doctors w...
- Brian Hill: While these doctors have looked at an overview of ...
- Big Tobacco Spending More Than a Super PAC to Defeat Cancer Research
- Actor’s Diagnosis Puts Spotlight on Oral Cancer
- Actor Michael Douglas Partners With Oral Cancer Foundation For Early Detection PSA Campaign
- 2009 Federal Tobacco Tax Increase Cut Number of Youth Smokers by At Least 220,000 in First Two Months Alone, New Study Shows
- Radiotherapy May Be Enough for HPV-Positive Throat Cancer
- Stem cell sparing radiotherapy for head and neck cancer may avoid salivary gland damage
- 1 of 6 cancer deaths worldwide caused by preventable infections
- Vaccination rates higher in states requiring them in middle school
- Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer
- Beastie Boys Co-Founder Adam Yauch Dead at 47
Follow OCF on these social networking sites connect to us, get involved, spread the knowledge, help the cause, change the world.
Tuesday, November 3, 2009
0 Comments